TriSalus Life Sciences announced the publication of clinical data evaluating its proprietary Pressure-Enabled Drug Delivery (PEDD) technology in thyroid parenchymal embolization, a new application for symptomatic thyroid disease. The retrospective single-center study by Gad et al., published in the Journal of the Endocrine Society, assessed the safety, feasibility, and early efficacy of Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav Infusion System.
The study concluded that PED-TAE is a safe and feasible treatment option for large goiters, potentially offering an alternative to more invasive approaches for benign thyroid nodules and benign multinodular goiters. This represents an expansion beyond the company's historic focus on improving treatment of liver cancers.
A multi-institutional registry study, PROTECT (NCT06868459), has been initiated in collaboration with TriSalus Life Sciences to further validate these findings and evaluate broader applicability in a multi-center setting. These early results reflect growing interest in the PEDD platform to expand minimally invasive treatment options for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.